ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2023

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present six oral and three poster presentations at the 65th American Society of Hematology (ASH) Meeting & Exposition, occurring in San Diego, California and virtually December 9 - 12, 2023. The presentations focus on treatments for acute leukemias and lymphoma.

Among the data are the promising results of the phase 2 PrE0405 trial, which evaluated bendamustine, rituximab, and venetoclax for the initial treatment of mantle cell lymphoma in older patients. Other abstracts are secondary analyses from the practice-changing E1910 phase 3 trial (Abstract LBA-1 at ASH 2022).

Details for the nine presentations are below, listed by type and date.

Oral Presentations

• The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia
  Presenter: Satoshi Yoshimura, MD (St. Jude Children's Research Hospital)
  Date and Time: Sunday, December 10, 4:45 PM
  Location: Grand Hall D, Manchester Grand Hyatt San Diego
  Abstract 596 in Session 618 (entire session 4:30-6:00 PM)
• Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN E2906 Phase 3 Trial
  Presenter: James M. Foran, MD (Mayo Clinic Florida)
  Date and Time: Sunday, December 10, 5:45 PM
  Location: Pacific Ballroom Salons 24-26, Marriott Marquis San Diego Marina
  Abstract 594 in Session 613 (entire session 4:30-6:00 PM)
• Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405)
  Presenter: Craig A. Portell, MD (University of Virginia Medical Center)
  Date and Time: Monday, December 11, 10:30 AM
  Location: Grand Hall B, Manchester Grand Hyatt San Diego
  Abstract 594 in Session 613 (entire session 4:30-6:00 PM)
• Single Cell Transcriptomic Analysis of B-Cell Acute Lymphoblastic Leukemia (B-ALL) Reveals Correlation between Leukemia Cell State, Genetic Alterations and Clinical Outcome
  Presenter: Ilaria Iacobucci, PhD (St. Jude Children's Research Hospital)
  Date and Time: Monday, December 11, 2:45 PM
  Location: Grand Hall D, Manchester Grand Hyatt San Diego
  Abstract 841 in Session 618 (entire session 2:45-4:15 PM)
• STAG2/LMO2 Gamma-Delta (γÎ') T-Cell Acute Lymphoblastic Leukemia: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young
  Presenter: Shunsuke Kimura, MD, PhD (St. Jude Children's Research Hospital)
  Date and Time: Monday, December 11, 3:45 PM
  Location: Grand Hall D, Manchester Grand Hyatt San Diego
  Abstract 845 in Session 618 (entire session 2:45-4:15 PM)
• Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)
  Presenter: Catherine S. Diefenbach, MD (Perlmutter Cancer Center at NYU Langone Health)
  Date and Time: Sunday, December 10, 4:30 PM
  Location: Grand Hall B, Manchester Grand Hyatt San Diego
  Abstract 607 in Session 624 (entire session 4:30-6:00 PM)

Poster Presentations

• Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial
  Presenter: Selina M. Luger, MD, FRCPC (University of Pennsylvania)
  Date and Time: Sunday, December 10, 6:00-8:00 PM
  Location: Halls G-H, San Diego Convention Center
  Abstract 2877 in Session 614
• AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
  Presenter: Tara O. Henderson, MD (University of Chicago Medical Center)
  Date and Time: Sunday, December 10, 6:00-8:00 PM
  Location: Halls G-H, San Diego Convention Center
  Abstract 3084 in Session 624
  ECOG-ACRIN participated in this trial through a collaboration across the National Cancer Institute's National Clinical Trials Network (NCTN).
• A Pro-Inflammatory Gene Signature Characterizes a Better Risk Aged Acute Myeloid Leukemia Patient Group in ECOG-ACRIN Cancer Research Group's Clinical Trial E3999
  Presenter: Yaseswini Neelamraju (University of Virginia)
  Date and Time: Monday, December 11, 6:00-8:00 PM
  Location: Halls G-H, San Diego Convention Center
  Abstract 4326 in Session 617